Logo

Aldeyra Therapeutics Entered into an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease

Share this

Aldeyra Therapeutics Entered into an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease

Shots:

  • Under the terms of the agreement, Aldeyra granted AbbVie an option to acquire a co-exclusive license & exclusive license to develop, manufacture & commercialize reproxalap across the US & ROW respectively
  • In return, Aldeyra will receive a non-refundable option fee worth $1M, an up front payment of $100M less option fee if exercised by AbbVie & is also eligible to receive up to $200M as commercial milestones & $100M as a regulatory milestone, plus tiered royalties on net sales of reproxalap across the US
  • Following the commercialization of reproxalap, AbbVie and Aldeyra will split the profits gained and losses faced as 60% and 40% respectively

Ref: Businesswire | Image: Aldeyra Therapeutics

Related News:- Aldeyra Therapeutics Reports the US FDA Acceptance of NDA for Reproxalap to Treat Dry Eye Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions